Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Skin Neoplasms × gusacitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Basal Cell Nevus Syndrome 2 Skin Neoplasms 1 Carcinoma, Basal Cell 1

Interventions

pembrolizumab 3 fludarabine 3 Cyclophosphamide 3 smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1 sargramostim 1 reolysin 1 poly ICLC 1 peginterferon alfa-2a 1 osimertinib 1 gusacitinib 1 fludarabine phosphate 1 eprenetapopt 1 dabrafenib 1 cobimetinib 1 cemiplimab 1 Vorinostat 1 Temozolomide 1 Radiotherapy 1 Radiation 1 Poly I-C 1 Nivolumab 1 Monatide (IMS 3015) 1 Methods 1 MAPRE1 protein, human 1 Ipilimumab 1 Interleukin-2 1 Interleukin-15 1 Interleukin-12 1 Histone Deacetylase Inhibitors 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02550678 2018-06-06

ASN-002-001

Ascend Biopharmaceuticals Ltd

Phase 1/2 Completed

Basal Cell Nevus Syndrome, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡